IN VIVO GENERATION OF ANGIOSTATIN 4.5--CLINICAL TRIAL

为了肿瘤的生长和转移，它们必须诱导 新血管的生成，这一过程被称为血管生成。 因此，抑制血管生成提供了一个重要的新的治疗靶点。 血管生成抑制剂Angiostatin是一种含有kringle的 纤溶酶原片段，已被证明能抑制肿瘤的生长 无数的动物模型。在西北大学之前由R01支持的工作中 大学，索夫等人。已经证明了原生生物的产生机制 人血管抑素。纤溶酶原首先被纤溶酶原转化为纤溶酶 激活剂，在游离的巯基供体存在下，纤溶酶经历 在Kringle 5内自我蛋白分解产生血管抑素4.5(AS4.5)，包括 前4 kringle以及85%kringle 5。AS4.5出现在 正常和恶性血液和其他标本，是一种有效的抑制 体内血管生成与肿瘤生长。特别令人感兴趣的是，最初 在患癌症的小鼠和人类身上进行实验，给药 抗血管生成鸡尾酒，由纤溶酶原激活剂和游离 巯基供体导致AS4.5水平显著升高，并抑制 肿瘤生长。虽然正在进行的工作仍在继续，以更好地了解 在AS4.5的体外活性方面，我们有兴趣更严格地研究 人类晚期恶性肿瘤患者体内产生AS4.5。这个 此快速试用拨款申请的重点是以第一阶段的方式确定 “鸡尾酒”中药物的安全剂量范围，即组织型纤溶酶原 激活剂(TPA)和Mesna。此外，我们将确定剂量反应 抗血管生成鸡尾酒中药物与血管紧张素转换酶水平的关系 AS4.5。这将允许严格计算原子的半衰期、体积 这一独特的活体生成的分布和曲线下面积 抗肿瘤治疗。

For tumors to grow and metastasize, they must induce the generation of new blood vessels, a process referred to as angiogenesis. Inhibition of angiogenesis thus provides an important new therapeutic target. The angiogenesis inhibitor angiostatin is a kringle-containing internal fragment of plasminogen, which has been shown to inhibit cancer growth in numerous animal models. In previous R01-supported work at Northwestern University, Soff et al. have demonstrated the mechanism of generation of native human angiostatin. Plasminogen is first converted to plasmin by a plasminogen activator, and in the presence of a free sulfhydryl donor, plasmin undergoes autoproteolysis within kringle 5 to yield Angiostatin 4.5(AS4.5), consisting of the first 4 kringles as well as 85 percent of kringle 5. AS4.5 is present in normal and malignant blood and other specimens and is a potent inhibitor of angiogenesis and cancer growth in vivo. Of particular interest, in initial experiments in mice and humans with cancer, administration of an antiangiogenesis cocktail, consisting of a plasminogen activator and a free sulfhydryl donor results in marked increases in AS4.5 levels and inhibition of tumor growth. While ongoing work continues in better understanding the nature in vitro of AS4.5 activity, we are interested in more rigorously studying the in vivo generation of AS4.5 in human patients with advanced malignancies. The focus of this quick trial grant application is to determine in Phase I fashion the safe dosage range of drugs in the "cocktail," namely tissue plasminogen activator (tPA) and mesna. In addition, we will determine the dose response relationship of the agents in the antiangiogenesis cocktail with the levels of AS4.5. This will allow a rigorous calculation of the half-life, volume of distribution and area under the curve of this uniquely in vivo-generated anti-neoplastic therapy.